Clinical Trial Update: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 biomarker-driven therapy trial in metastatic colorectal cancer sponsored by Hoffmann-La Roche has completed with results posted in July 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Biomarker-driven therapy (unspecified agent)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-07-24